Instant Messaging
Video Call
Xiamen Wantai Canghai Biotechnology Co., Ltd.
Manufacturing of biological drugs; manufacturing of medical diagnosis, monitoring and treatment equipment; manufacturing of other basic chemical raw materials (excluding hazardous chemicals, monitoring chemicals, and non-drug precursor chemicals); operating the import and export of various commodities and technologies (not A catalog of import and export commodities is also attached), with the exception of commodities and technologies that the state restricts companies to operate or prohibits import and export; biotechnology promotion services; other unspecified animal breeding; engineering and technological research and experimental development.
Sell
- No classification
Search
Honor
- No classification
Elite|
|
|
Introduction
Wantai Canghai Biotechnology Co., Ltd. Wantai Canghai is a private technology company engaged in vaccine research and development. In 2012, it launched the world's first hepatitis E vaccine, and in 2019, it launched the world's fourth and first domestic cervical cancer vaccine-Xinkening® . Product introduction: Hepatitis E vaccine: Yikening® The world's first hepatitis E vaccine on the market Unique E. coli expression platform: efficient and safe Have a high degree of independent intellectual property rights: multiple international and domestic invention patents Papillomavirus vaccine: Xinkening® National Class A new drug, the first domestically approved HPV vaccine The third cervical cancer vaccine supplier in the world More cost-effective, the first domestically approved 2 injections for 9-14 years old Immunization program
[Detailed introduction]
Products
-
Wantai vaccine
2021-07-11
-
Recombinant hepatitis E vaccine
2021-07-11
Photo